Clorox Is Cheap For A Reason, And The Reason Is Debt

# Clorox Is Cheap For A Reason, And The Reason Is Debt

Clorox is down 37% off its 52-week high and sitting right on its 52-week low at roughly $80.65. The dividend yield has ballooned to 6.2%. Morningstar just named it one of its "10 Best Companies to Invest in Now" with a fair-value target of $154 — nearly double the current price.

So why does the street look at a half-off consumer-staples staple and shrug?

Because what used to be a "buy it and forget it" holding is no longer that. The tape is telling you something, and it isn't "bargain."

The Fundamentals Are Actually Breaking

Let's be precise about what happened. FY2026 revenue fell 5.4% to $6.72 billion. Q4 sales were down 13% on an organic basis. Net income collapsed roughly 27.5% to about $587 million. Gross margin compressed to roughly 41.3%, and operating margin fell to 12.6%.

Management points at the SAP ERP transition and says the U.S. retailers front-loaded orders in fiscal 2025, then drew down inventory during the rollout — which crushed shipments. That's a real explanation, not just management-speak. The GOJO acquisition, closed April 1, added inventory step-up charges and, critically, debt.

But explanations aren't balance sheets.

Here's The Part People Are Ignoring

Total liabilities jumped about 48% to $7.54 billion after the GOJO deal. Shareholders' equity is thin. Cash sits at $143 million. The company ran negative working capital of about -$949 million, and first-quarter FY2027 operating cash flow was negative $122 million.

And the dividend? Free cash flow did not cover it. Management itself called the payout ratio "a bit elevated" — landing anywhere from 85% to over 100% depending on how you measure it.

This is a company that just took on real leverage, ran its payout past what its cash can back, and is navigating a messy systems transition and an integration all at once. The debt-to-equity reading is ugly. Nobody is saying Clorox goes broke. Nobody's saying much of anything bullish about the next quarter.

What The Bulls Actually Have

I'll give them their points. GOJO is now expected to be EPS-accretive in FY2027, not dilutive. The new Purell ProCare B2B platform — folding CloroxPro and GOJO under one health-and-hygiene umbrella — launched this fall. And management is guiding FY2027 net sales up 13–14%, gross margin around 42%, adjusted EPS of $5.70 to $6.00.

That guidance is the whole bull case: the trough is behind us, the recovery is coming, and at a forward P/E near 14x you're buying quality on sale.

Fine. But guidance is a wish with a spreadsheet behind it, and this management team is currently wishing through an ERP migration and a balance sheet built on confidence, not cushion.

My Read

The technicals agree the tape is weak. Clorox sits below its 20-, 50-, and 200-day averages — 20% under that 200-day line — with an RSI hovering near oversold at 30. There's a floor near $79–80 where buyers have stepped in, and real resistance at the $100–105 zone where people trapped at the top will try to exit.

Some models are throwing a bullish relief-rally signal toward the low triple digits. But that signal has been beaten by the naive "keep doing what it's doing" baseline, which means I trust it less, not more. A dead-cat bounce off a 52-week low is still a dead cat.

So here's the playbook:

• This is an accumulate-on-strength name, not a chase-the-breakout name. If Clorox reclaims its 20-day average and holds above $85 with volume, we have a base. Until then, it's a downtrend with a dividend.
• The dividend is the reason to care, not the reason to overpay. 6.2% is genuinely attractive — but a payout the cash can't cover near a leverage high is exactly the kind of thing that gets cut, and the market will re-rate you down hard if it does.
• The real catalysts are close: the ex-dividend date is October 28, and next earnings land November 3. That's your decision window, not the current noise.

Clorox isn't a value trap in the sense of going away. It's a value trap in the more dangerous sense: it looks cheap enough to make patient people do impatient things. Buy the leverage, buy the thin equity, buy the uncovered dividend — and then be patient about believing the recovery story until the numbers prove it.

The tape says wait for the base. I'll take the tape.